15 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.
Shandong University
Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation.
Epizyme, Inc.
Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
Daiichi Sankyo Co., Ltd
Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2.
Sun Yat-Sen University
Recent advances in targeting histone H3 lysine 36 methyltransferases for cancer therapy.
China Pharmaceutical University
Recent advances in nuclear receptor-binding SET domain 2 (NSD2) inhibitors: An update and perspectives.
China Pharmaceutical University
NSD3: Advances in cancer therapeutic potential and inhibitors research.
Peking University
Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2).
University of Texas Medical Branch (UTMB)
Discovery of a New-Generation S-Adenosylmethionine-Noncompetitive Covalent Inhibitor Targeting the Lysine Methyltransferase Enhancer of Zeste Homologue 2.
Sun Yat-Sen University
Discovery of cysteine-targeting covalent histone methyltransferase inhibitors.
Nanjing Medical University
Structural Modification and Pharmacological Evaluation of Substituted Quinoline-5,8-diones as Potent NSD2 Inhibitors.
Shanghai Jiao Tong University
From Hit Seeking to Magic Bullets: The Successful Union of Epigenetic and Fragment Based Drug Discovery (EPIDD + FBDD).
University of S£O Paulo
5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.
Chinese Academy of Sciences
